Bar-Ilan University Announces Nano-Drop Candidate to Correct Refractive Error

March 16, 2018: By Joan McKenna

Bar-Ilan University in Israel announced March 8 that it is developing an eye drop filled with synthetic nanoparticles as a non-invasive method to correct refractive errors.

Researchers previously described their work at the 2017 meeting of the European Society of Cataract and Refractive Surgeons.

The eye drops, branded Nano-Drops, work in conjunction with a laser source to apply an optical pattern to the superficial layer of the corneal epithelium to change the refractive index, or the trajectory of light passing through the cornea, according to developers. Surgeons can adjust the shape of the pattern for correction of myopia, hyperopia, or presbyopia.

The university said the laser stamping takes a few milliseconds.

Bar-Ilan said a future use might consist of patients having their vision corrected in the comfort of their own home. The school envisions patients opening an application on their smartphone to measure their vision, connecting the laser source device for stamping the optical pattern at the desired correction, and applying the Nano-Drops to activate the pattern and provide the desired correction.

The university said the technology has shown through ex-vivo experiments that it can correct nearly 3 diopters of myopia and presbyopia in pig eyes.

Need Deeper Analysis? Sign up for Market Scope's monthly newsletter to get in-depth coverage of the ophthalmic market, including quarterly procedure volumes based on survey data and meeting coverage from around the world.

Recent Ophthalmic News

US FDA Grants De Novo Request for IDx-DR’s AI Diagnostic System for Diabetic Retinopathy

Allergan Launches TrueTear Intranasal Neurostimulation Device for Dry Eye

Novartis Acquires AveXis, Gene Therapy Platform for $8.7 Billion

Samsung, Biogen Reach Deal with AbbVie over Humira Biosimilar

EyePoint Secures Two US Patents for DEXYCU

SightLife Surgical Rebrands as CorneaGen, Offers New Products

Omidria Earns Listing on VA Formulary, Regains CMS Pass-Through Status

Rayner Launching 600C Monofocal Aspheric IOL in US

LENSAR Laser System Receives 510(k) Clearance for Corneal Pockets, Flaps

EyeGate Completes Enrollment, Receives Milestone Payment for Phase III Study of EGP-437 in Anterior Uveitis

SAV-IOL Seeks $20M in Financing for Active Intraocular Lens Concept with Real-Time Autofocus

AGTC Completes Enrollment for Phase I/II Study of Gene Therapy for X-linked Retinoschisis

Robert Greenberg, MD, PhD, Resigns from Second Sight

US FDA Requires RegeneRx to Conduct Third Phase III Trial for Dry Eye Candidate RGN-259

Stem Cell Implant Yields Positive Results in Phase I/II Study in Dry AMD

Drug Companies Petition Supreme Court to Hear Case Challenging Eye Drop Size

Appeals Court Rules in Favor of Alcon in Suit Brought by Elenza over EAIOLs

ThromboGenics’ THR-137 Demonstrates Safety, Tolerability in Phase I/II Study in DME

GenSight Biologics’ LHON Candidate Improves Eyesight, Fails to Outpace Sham in Phase III Trial

I-MED Pharma’s I-PEN Receives Regulatory Approval in Colombia, Argentina

Coming soon

2018 China Ophthalmic Market Report: An Analysis for 2017 to 2023